Scott Shoemaker - Bluebird Bio Senior Quality
| BLUE Stock | USD 0.38 0.01 2.70% |
Executive
Scott Shoemaker is Senior Quality of Bluebird bio
| Address | 455 Grand Union Boulevard, Somerville, MA, United States, 02145 |
| Phone | 339 499 9300 |
| Web | https://www.bluebirdbio.com |
Bluebird Bio Management Efficiency
The company has return on total asset (ROA) of (0.3624) % which means that it has lost $0.3624 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.867) %, meaning that it created substantial loss on money invested by shareholders. Bluebird Bio's management efficiency ratios could be used to measure how well Bluebird Bio manages its routine affairs as well as how well it operates its assets and liabilities. As of November 30, 2024, Return On Tangible Assets is expected to decline to -0.37. In addition to that, Return On Capital Employed is expected to decline to -0.61. At present, Bluebird Bio's Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Intangible Assets is expected to grow to about 10.8 M, whereas Other Assets are forecasted to decline to about 33.2 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Hubert MD | Krystal Biotech | 55 | |
| Laurent Goux | Krystal Biotech | N/A | |
| FACNP FACP | Y mAbs Therapeutics | 76 | |
| MSc MD | Y mAbs Therapeutics | 60 | |
| Daniel Trepanier | Hepion Pharmaceuticals | N/A | |
| John Thomas | Krystal Biotech | N/A | |
| Jennifer Towne | Vir Biotechnology | N/A | |
| CPA CPA | Viking Therapeutics | 53 | |
| Lee MD | PTC Therapeutics | 56 | |
| Ronald Plasterk | CureVac NV | N/A | |
| Elhan CFA | Karyopharm Therapeutics | N/A | |
| MBA EdD | Vir Biotechnology | N/A | |
| Slavica StevanovicHeck | CureVac NV | N/A | |
| Jula MD | Travere Therapeutics | 49 | |
| Pierre MS | PTC Therapeutics | 38 | |
| Christopher Taylor | Agios Pharm | N/A | |
| Marc Damelin | Mersana Therapeutics | N/A | |
| Tsveta Milanova | Agios Pharm | 47 | |
| Adrian MD | Zentalis Pharmaceuticals Llc | N/A | |
| Ulrike MD | CureVac NV | 51 | |
| Sarah Connors | Karyopharm Therapeutics | N/A | |
Management Performance
| Return On Equity | -1.87 | ||||
| Return On Asset | -0.36 |
Bluebird bio Leadership Team
Elected by the shareholders, the Bluebird Bio's board of directors comprises two types of representatives: Bluebird Bio inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Bluebird. The board's role is to monitor Bluebird Bio's management team and ensure that shareholders' interests are well served. Bluebird Bio's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Bluebird Bio's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Andrew Obenshain, CEO President | ||
| Mr MD, Chief Officer | ||
| Melissa Bonner, VP Research | ||
| Andrea Walton, Chief Officer | ||
| JD Esq, Chief Secretary | ||
| Christopher CPA, Principal CFO | ||
| Elizabeth Pingpank, Director Communications | ||
| Richard MD, Chief Officer | ||
| Jess Rowlands, Head Communications | ||
| Liviu MD, VP Affairs | ||
| Kasra Kasraian, Senior Operations | ||
| Scott Shoemaker, Senior Quality | ||
| Oliver III, CFO Officer | ||
| Sarah Alspach, Senior Affairs | ||
| Thomas Klima, Chief COO |
Bluebird Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Bluebird Bio a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.87 | ||||
| Return On Asset | -0.36 | ||||
| Operating Margin | (5.49) % | ||||
| Current Valuation | 371.21 M | ||||
| Shares Outstanding | 194.44 M | ||||
| Shares Owned By Insiders | 0.63 % | ||||
| Shares Owned By Institutions | 43.68 % | ||||
| Number Of Shares Shorted | 43.64 M | ||||
| Price To Earning | (19.32) X | ||||
| Price To Book | 0.73 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Bluebird bio is a strong investment it is important to analyze Bluebird Bio's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Bluebird Bio's future performance. For an informed investment choice regarding Bluebird Stock, refer to the following important reports:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bluebird bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment. For information on how to trade Bluebird Stock refer to our How to Trade Bluebird Stock guide.You can also try the Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bluebird Bio. If investors know Bluebird will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bluebird Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.80) | Revenue Per Share 0.357 | Quarterly Revenue Growth 1.337 | Return On Assets (0.36) | Return On Equity (1.87) |
The market value of Bluebird bio is measured differently than its book value, which is the value of Bluebird that is recorded on the company's balance sheet. Investors also form their own opinion of Bluebird Bio's value that differs from its market value or its book value, called intrinsic value, which is Bluebird Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bluebird Bio's market value can be influenced by many factors that don't directly affect Bluebird Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bluebird Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Bluebird Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bluebird Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.